Carvedilol or propranolol in portal hypertension? A randomized comparison

References

• Hobolth L, Krag A, Bendtsen F. The recent reduction in mortality from bleeding oesophageal varices is primarily observed from days 1 to 5. Liver Int 2010;30:455–62.
   PubMed Web of Science ®Google Scholar
• Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419–24.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611–24.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475–505.
   PubMed Web of Science ®Google Scholar
• Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952–4.
   PubMed Web of Science ®Google Scholar
• Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116–26.
   PubMed Web of Science ®Google Scholar
• Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–9.
   PubMed Web of Science ®Google Scholar
• Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007;9:269–77.
   PubMed Web of Science ®Google Scholar
• Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909–15.
   PubMed Web of Science ®Google Scholar
• Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002;16:373–80.
   PubMedGoogle Scholar
• Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999;30:479–84.
   PubMed Web of Science ®Google Scholar
• Sekiyama T, Komeichi H, Nagano T, Ohsuga M, Terada H, Katsuta Y, Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Arzneimittelforschung 1997;47:353–5.
   PubMedGoogle Scholar
• Bruha R, Vitek L, Petrtyl J, Lenicek M, Urbanek P, Zelenka J, Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scand J Gastroenterol 2006;41:1454–63.
   PubMed Web of Science ®Google Scholar
• Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367–73.
   PubMed Web of Science ®Google Scholar
• De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D, Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002;17:183–9.
   PubMedGoogle Scholar
• Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de DA, Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999;30:79–83.
   PubMed Web of Science ®Google Scholar
• Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004;99:1953–8.
   PubMed Web of Science ®Google Scholar
• Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987;7:648–53.
   PubMed Web of Science ®Google Scholar
• La MV, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia-Pagan JC, Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009;51:279–87.
   PubMedGoogle Scholar
• Villanueva C, Aracil C, Colomo A, Hernandez-Gea V, Lopez-Balaguer JM, varez-Urturi C, Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009;137:119–28.
   PubMed Web of Science ®Google Scholar
• Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005;22:433–9.
   PubMedGoogle Scholar
• Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987;5:144–8.
   PubMedGoogle Scholar
• Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest Suppl 1966;18:118–25.
   PubMedGoogle Scholar
• Bendtsen F, Henriksen JH, Sørensen TI. Propranolol and haemodynamic response in cirrhosis. J Hepatol 1991;13:144–8.
   PubMed Web of Science ®Google Scholar
• Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825–33.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902–8.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101–6.
   PubMed Web of Science ®Google Scholar
• Albillos A, Garcia-Pagan JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998;115:116–23.
   PubMed Web of Science ®Google Scholar